HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme [letter]

E Florence; S De Wit; A Castagna; E Ribera; A Hill; H Vanaken; Y van Delft; S Marks

doi:10.1258/ijsa.2009.009425

HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme [letter]

E Florence, S De Wit, A Castagna, E Ribera, A Hill, H Vanaken, Y van Delft, S Marks

Research output: Contribution to journal › Letter › peer-review

Original language	English
Journal	International Journal of STD & AIDS
Volume	21
Issue number	3
Pages (from-to)	224-225
Number of pages	2
ISSN	0956-4624
DOIs	https://doi.org/10.1258/ijsa.2009.009425
Publication status	Published - 2010

Keywords

B780-tropical-medicine
Viral diseases
HIV
AIDS
HAART
Antiretrovirals
Etravirine
Darunavir
Ritonavir
Raltegravir
RNA suppression
CD4 lymphocyte count
Efficacy
Clinical trials

Access to Document

10.1258/ijsa.2009.009425

http://lib.itg.be/pdf/itg/2010/2010ijsa0224.pdf

Cite this

@article{f2398183b53246e0bf6f7745a5b36951,

title = "HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme [letter]",

keywords = "B780-tropical-medicine, Viral diseases, HIV, AIDS, HAART, Antiretrovirals, Etravirine, Darunavir, Ritonavir, Raltegravir, RNA suppression, CD4 lymphocyte count, Efficacy, Clinical trials",

author = "E Florence and {De Wit}, S and A Castagna and E Ribera and A Hill and H Vanaken and {van Delft}, Y and S Marks",

note = "ITG-C1A; CLINIC; U-HIVCLI; JIF; DOI; PDF; DSPACE",

year = "2010",

doi = "10.1258/ijsa.2009.009425",

language = "English",

volume = "21",

pages = "224--225",

journal = "International Journal of STD & AIDS",

issn = "0956-4624",

publisher = "Sage Publications",

number = "3",

}

HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme [letter]. / Florence, E; De Wit, S; Castagna, A; Ribera, E; Hill, A; Vanaken, H; van Delft, Y; Marks, S.

In: International Journal of STD & AIDS, Vol. 21, No. 3, 2010, p. 224-225.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme [letter]

AU - Florence, E

AU - De Wit, S

AU - Castagna, A

AU - Ribera, E

AU - Hill, A

AU - Vanaken, H

AU - van Delft, Y

AU - Marks, S

N1 - ITG-C1A; CLINIC; U-HIVCLI; JIF; DOI; PDF; DSPACE

PY - 2010

Y1 - 2010

KW - B780-tropical-medicine

KW - Viral diseases

KW - HIV

KW - AIDS

KW - HAART

KW - Antiretrovirals

KW - Etravirine

KW - Darunavir

KW - Ritonavir

KW - Raltegravir

KW - RNA suppression

KW - CD4 lymphocyte count

KW - Efficacy

KW - Clinical trials

U2 - 10.1258/ijsa.2009.009425

DO - 10.1258/ijsa.2009.009425

M3 - Letter

VL - 21

SP - 224

EP - 225

JO - International Journal of STD & AIDS

JF - International Journal of STD & AIDS

SN - 0956-4624

IS - 3

ER -